Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent

Trial Profile

Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Tasadenoturev (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2017 Results assessing safety, efficacy and prognostic biomarkers of DNX-2401 treatment response, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 17 Nov 2016 Data from this trial will be presented at the 21st Annual Meeting of the Society for Neuro-Oncology, according to a DNAtrix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top